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Abstract: Quaternary amino acids containing a geminal bisphos-
phonate moiety have been synthesized for the first time. The devel-
oped two-step reaction sequence utilizes the Michael addition of α-
substituted azlactones to a vinylidene bisphosphonate as the key
step. The reaction proceeds under catalytic conditions with excel-
lent regioselectivity. Subsequent, acid-mediated azlactone ring
opening affords the target quaternary amino acids with good overall
yields. Attempts to develop an enantioselective version of the syn-
thetic strategy are described.
Key words: azlactones, quaternary amino acids, geminal bisphos-
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Target-oriented synthesis of specific structural motives
important for medicinal chemistry constitutes an import-
ant goal in modern organic chemistry.1 Among different
biologically relevant molecules, quaternary amino acids
occupy a prominent position due to their interesting bio-
logical properties (Scheme 1).2 For example, incorpora-
tion of this structural motif into biomolecules can result in
improved biostability due to the presence of the quaterna-
ry carbon atom.3 Geminal bisphosphonates constitute an-
other important group of pharmacologically active
compounds that have found application in the treatment of
several bone disorders such as Paget’s disease, myeloma,
bone metastases, or osteoporosis.4 As both groups of com-
pounds have interesting biological properties, it was antic-
ipated that merging their pharmacological potential may
lead to the development of a novel class of biologically
active molecules.
α-Substituted azlactones constitute an important group of
quaternary amino acid precursors that have found wide-
spread application in contemporary organic synthesis.5
Their ability to undergo Michael additions is well recog-
nized.6 Surprisingly, to the best of our knowledge no re-
ports on Michael addition of azlactones to phosphoryl
group stabilized Michael acceptors exists in the literature.
We designed a route that incorporated a quaternary amino
acid moiety into the side chain of a geminal bisphospho-
nate which relied on the Michael addition of an α-substi-
tuted azlactone to a vinylidene bisphosphonate.7
However, at the outset of our studies important challenges
related to the regioselectivity of the reaction had to be
considered. It is well recognized that azlactones display
nucleophilicity both in the C2 and C4 positions (Scheme
2). Furthermore, O-alkylation constitutes another possi-
bility.
Scheme 1  Relevance of amino acid and geminal bisphosphonate
moieties in chemistry and biology
Scheme 2  Reactivity of azlactones
Herein, we report the first example of a Michael reaction
between an α-substituted azlactone and a vinylidene bis-
phosphonate (Scheme 3). The developed catalytic ap-
proach benefits from operational simplicity and easily
available starting materials. The possibility to open the az-
lactone moiety for the synthesis of quaternary amino acids
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is demonstrated. Furthermore, attempts for the develop-
ment of an enantioselective version of the reaction em-
ploying chiral Brønsted base catalysis were undertaken.
Importantly, this reaction results in the formation of qua-
ternary stereocenter containing molecules, which is an im-
portant and challenging task in modern organic synthesis.8
Scheme 3  Novel approach to the quaternary amino acids containing
geminal bisphosphonate moiety
Studies were initiated with the goal of finding optimal
conditions for the devised Michael addition. Tetraethyl
ethene-1,1-diylbis(phosphonate) (3a) was chosen as a
model Michael acceptor. Initial screening revealed that
the devised Michael reaction can be performed employing
a catalytic amount of base. Triethylamine was identified
as the best base and dichloromethane as the optimal sol-
vent. Under these conditions the Michael reaction em-
ploying α-benzyl-substituted azlactone 4a as a donor was
terminated within 24 hours affording 2a in a high 88%
yield. Under these conditions the scope of the methodolo-
gy was investigated (Table 1). It was found that various
substituents could be present in the α-position of starting
azlactones 4a–f. Branching in the alkyl chain of 4b–c led
to yield deterioration as demonstrated in the synthesis of
2b and 2c. The effect was particularly pronounced in the
case of 2c. Simple methyl-substituted azlactone 4d also
underwent the Michael reaction, albeit the formation of
small amounts of the C2 regioisomer was observed. Good
results were obtained with the phenyl-substituted azlac-
tone 4e demonstrating the possibility of introducing an
aromatic moiety at the C2 position of the target amino
acid 2e. Finally, the introduction of a heteroatom in the
side chain of the starting azlactone 4f was attempted. In
this case the reaction proceeded efficiently affording 2f as
a single regioisomer in good yield.
Further studies were focused on the transformation of α,α-
disubstituted azlactones 2a–f thus obtained into the de-
sired quaternary amino acids 1a–f. Gratifyingly, it was
found that under standard reaction conditions9 the azlac-
tone moiety can be efficiently opened, affording linear
amino acids 1a–f bearing the geminal bisphosphonate
moiety (Table 2). In all cases moderate to good yields
were obtained confirming the generality of the developed
synthetic methodology.
The possibility to perform the reaction under basic condi-
tions prompted us to investigate an enantioselective ver-
sion of the reaction employing different chiral Brønsted
bases (Scheme 4). Initial studies showed that the use of
simple cinchona alkaloid 5a afforded target adduct 2b
with 37% ee. Attempts were made to improve the enanti-
oselectivity of the reaction by a simple modification of the
catalyst employed. Therefore, different cinchona alka-
loids 5a,b and their derivatives 5c–e were evaluated in the
reaction. Disappointingly, cinchonidine (5b) afforded the
target product 2b as a racemic mixture. Similarly, em-
ployment of the bifunctional catalysts 5c and 5d bearing
double H-bonding moieties led to the deterioration of en-
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Table 1  Michael Addition of α-Substituted Azlactones 4 to Tetra-
ethyl Ethene-1,1-diylbis(phosphonate) (3a)a
Entry R Regioisomeric ratiob Yield (%)
1 Bn (4a) >20:1 88 (2a)
2 i-Bu (4b) >20:1 55 (2b)
3 i-Pr (4c) >20:1 44 (2c)
4 Me (4d) 5:1 49 (2d)
5 Ph (4e) >20:1 63 (2e)
6 CH2CH2SMe (4f) >20:1 65 (2f)
a Reactions performed on 0.25-mmol scale (for details see the exper-
imental section).
b Regioisomeric ratio as determined by 1H NMR of a crude reaction 
mixture.
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Table 2  Synthesis of Quaternary Amino Acids via Acid-Mediated 
Azlactone Ring Openinga
Entry R Yield (%)
1 Bn (2a) 58 (1a)
2 i-Bu (2b) 53 (1b)
3 i-Pr (2c) 51 (1c)
4 Me (2d) 47 (1d)
5 Ph (2e) 43 (1e)
6 CH2CH2SMe (2f) 56 (1f)
a Reactions performed on 0.1-mmol scale (for details see the experi-
mental section).
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antioselectivity. Furthermore, the use of dimeric cinchona
alkaloid catalyst 5e did not lead to an improvement in the
enantioselectivity of the reaction. Further studies on the
enantioselective version of the reaction are ongoing in our
laboratories.
In conclusion, we have developed a new approach to a
new class of α,α-disubstituted α-amino acid. It utilizes a
two-step reaction sequence consisting of Michael addition
of α-substituted azlactones 4 to tetraethyl ethene-1,1-diyl-
bis(phosphonate) (3a) followed by azlactone ring opening
under acidic conditions. The first step of the developed
synthetic strategy could be performed under basic, cata-
lytic conditions. Initial attempts to develop an enantiose-
lective version of this reaction have been demonstrated.
The presence of a geminal bisphosphonate moiety in the
side chain of the target amino acids may lead to products
with interesting biological properties.
Azlactones 4a–f and tetraethyl ethene-1,1-diylbis(phosphonate)
(3a) were prepared according to literature procedures.10 1H and 13C
NMR spectra were recorded on a Bruker Ultra Shield 700 instru-
ment. 1H NMR with the solvent reference relative to TMS em-
ployed as the internal standard (CDCl3, δ = 7.26); 13C NMR relative
to TMS with the respective solvent resonance as the internal stan-
dard (CDCl3, δ = 77.16). 31P NMR spectra were recorded either on
a Bruker Ultra Shield 700 or Bruker Avance DPX 250 spectrometer
at r.t. in CDCl3 as a solvent using 85% H3PO4 as external standard.
Flash chromatography was performed on Merck silica gel (60, par-
ticle size: 35–70 μm). TLC was carried out on commercially avail-
able pre-coated plates (Silica on TLC Alu foils, Fluka) and
visualized by UV light. Catalysts, which are commercially available
reagents, were purchased from Aldrich and used as received. Cin-
chona-derived catalysts 5c–d were synthesized following the proce-
dures reported in the literature.11 Enantiomeric excess of adduct 2b
was determined by chiral stationary phase HPLC using Daicel Chi-
ralpak IC column. 
Michael Addition of α-Substituted Azlactones 4 to Tetraethyl 
Ethene-1,1-diylbis(phosphonate) (3a); General Procedure
An ordinary screw-cap vial was charged with a magnetic stirring
bar, CH2Cl2 (1 mL), tetraethyl vinylbisphosphonate (3a, 0.25 mmol,
1 equiv) and Et3N (0.05 mmol, 0.2 equiv). Subsequently, azlactone
4 (0.25 mmol, 1 equiv) was added and the resulting mixture was
stirred at r.t. for 24 h. After this time the mixture was directly sub-
jected to flash column chromatography (silica gel) to afford target
product 2.
Tetraethyl [2-(4-Benzyl-5-oxo-2-phenyl-4,5-dihydrooxazol-4-
yl)ethane-1,1-diyl]bis(phosphonate) (2a)
Following the general procedure using (EtOAc–MeOH, 95:5) gave
2a as a single regioisomer as a pale yellow oil; yield: 121.8 mg
(88%).
1H NMR (700 MHz, CDCl3): δ = 7.83–7.81 (m, 2 H), 7.53–7.49 (m,
1 H), 7.41 (t, J = 7.8 Hz, 2 H), 7.14–7.11 (m, 5 H), 4.22–4.14 (m, 4
H), 4.13–4.05 (m, 4 H), 3.18 (d, J = 13.4 Hz, 1 H), 3.15 (d, J = 13.4
Hz, 1 H), 2.83–2.62 (m, 3 H), 1.35 (t, J = 7.0 Hz, 3 H), 1.34 (t, J =
6.9 Hz, 3 H), 1.24 (t, J = 7.1 Hz, 6 H).
13C NMR (176 MHz, CDCl3): δ = 178.8, 160.8, 133.7, 132.5, 130.4
(2 C), 128.6 (2 C), 128.0 (2 C), 127.8 (2 C), 127.3, 125.8, 72.3 (dd,
J = 9.3, 2.4 Hz), 63.0 (d, J = 6.4 Hz), 62.8 (d, J = 7.4 Hz), 62.7 (d,
Scheme 4  Asymmetric synthesis of quaternary amino acid 2b
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J = 7.7 Hz), 62.7 (d, J = 7.1 Hz), 45.4, 32.3 (dd, J = 135.3, 132.7
Hz), 32.0 (t, J = 3.9 Hz), 16.4 (d, J = 6.5 Hz), 16.3 (d, J = 6.4 Hz),
16.2 (d, J = 5.5 Hz, 2 C).
31P NMR (101 MHz, CDCl3): δ = 23.96, 23.63.
HRMS: m/z [M + H]+ calcd for C26H36NO8P2: 552.1911; found:
552.1915.
Tetraethyl [2-(4-Isobutyl-5-oxo-2-phenyl-4,5-dihydrooxazol-4-
yl)ethane-1,1-diyl]bis(phosphonate) (2b)
Following the general procedure (EtOAc–MeOH, 95:5) gave 2b as
a single regioisomer as a pale yellow oil; yield: 71.3 mg (55%).
1H NMR (700 MHz, CDCl3): δ = 8.01–7.99 (m, 2 H), 7.58–7.55 (m,
1 H), 7.48 (t, J = 7.8 Hz, 2 H), 4.20–4.13 (m, 4 H), 4.13–4.04 (m, 4
H), 2.70 (dddd, J = 25.3, 23.8, 6.6, 3.2 Hz, 1 H), 2.61–2.45 (m, 2 H),
1.91 (dd, J = 14.2, 5.7 Hz, 1 H), 1.81 (dd, J = 14.1, 6.4 Hz, 1 H),
1.58 (nonet, J = 13.0 Hz, 1 H), 1.33 (q, J = 6.9 Hz, 6 H), 1.24 (dt,
J = 8.3, 7.1 Hz, 6 H), 0.87 (d, J = 6.6 Hz, 6 H).
13C NMR (176 MHz, CDCl3): δ = 180.1, 160.4, 132.7, 128.8 (2 C),
127.9 (2 C), 126.0, 70.8 (dd, J = 7.9, 3.0 Hz), 62.9 (d, J = 6.5 Hz),
62.7 (d, J = 6.5 Hz, 3 C), 47.6, 33.0 (t, J = 4.3 Hz), 31.9 (d, J = 135.4,
134.7 Hz), 24.7, 24.1, 23.6, 16.3 (d, J = 6.2 Hz), 16.3 (d, J = 6.2 Hz),
16.2 (d, J = 5.7 Hz), 16.2 (d, J = 5.7 Hz).
31P NMR (101 MHz, CDCl3): δ = 24.08, 23.78.
HRMS: m/z [M + H]+ calcd for C23H38NO8P2: 518.2067; found:
518.2072.
Tetraethyl [2-(4-Isopropyl-5-oxo-2-phenyl-4,5-dihydrooxazol-
4-yl)ethane-1,1-diyl]bis(phosphonate) (2c)
Following the general procedure (EtOAc–MeOH, 95:5) gave 2c as
a single regioisomer as a pale yellow oil; yield: 55.0 mg (44%).
1H NMR (700 MHz, CDCl3): δ = 8.01–7.99 (m, 2 H), 7.58–7.54 (m,
1 H), 7.49–7.45 (m, 2 H), 4.21–4.14 (m, 4 H), 4.13–4.01 (m, 4 H),
2.73–2.55 (m, 3 H), 2.08 (hept, J = 6.8 Hz, 1 H), 1.34 (t, J = 7.1, Hz,
3 H), 1.34 (t, J = 7.3 Hz, 3 H), 1.25 (t, J = 7.1 Hz, 3 H), 1.22 (t, J =
7.1 Hz, 3 H), 1.02 (d, J = 6.8 Hz, 3 H), 0.98 (d, J = 6.8 Hz, 3 H).
13C NMR (176 MHz, CDCl3): δ = 179.3, 161.0, 132.6, 128.7 (2 C),
127.9 (2 C), 126.0, 73.3 (d, J = 9.6 Hz), 62.9 (d, J = 6.2 Hz), 62.7
(d, J = 5.9 Hz, 2 C), 62.6 (d, J = 5.1 Hz), 37.2, 32.1 (dd, J = 135.7,
133.5 Hz), 29.9 (t, J = 3.9 Hz), 16.7, 16.4, 16.4 (d, J = 6.4 Hz), 16.3
(d, J = 6.5 Hz), 16.2 (d, J = 5.9 Hz), 16.2 (d, J = 5.6 Hz).
31P NMR (101 MHz, CDCl3): δ = 24.25, 24.03.
HRMS: m/z [M + H]+ calcd for C22H36NO8P2: 504.1911; found:
504.1919.
Tetraethyl [2-(4-Methyl-5-oxo-2-phenyl-4,5-dihydrooxazol-4-
yl)ethane-1,1-diyl]bis(phosphonate) (2d)
Following the general procedure (EtOAc–MeOH, 95:5) gave 2d as
a mixture of regioisomers as a yellow oil; yield: 58.5 mg (49%); ra-
tio 5:1.
1H NMR (700 MHz, CDCl3): δ = 8.01–7.97 (m, 2 H), 7.58–7.55 (m,
1 H), 7.49–7.46 (m, 2 H), 4.22–4.15 (m, 4 H), 4.14–4.05 (m, 4 H),
2.72 (dddd, J = 25.7, 23.5, 7.4, 2.9 Hz, 1 H), 2.61 (ddt, J = 18.6,
15.1, 7.4 Hz, 1 H), 2.50 (dddd, J = 23.0, 19.7, 15.2, 3.0 Hz, 1 H),
1.53 (s, 3 H), 1.35 (t, J = 6.7 Hz, 3 H), 1.34 (t, J = 6.9 Hz, 3 H), 1.25
(t, J = 7.2 Hz, 3 H), 1.24 (t, J = 7.2 Hz, 3 H).
13C NMR (176 MHz, CDCl3): δ = 180.0, 160.9, 132.9, 128.9 (2 C),
128.1 (2 C), 126.2, 67.3 (dd, J = 9.2, 2.9 Hz), 63.1 (d, J = 6.7 Hz),
62.9 (d, J = 6.7 Hz), 62.8 (d, J = 6.4 Hz, 2 C), 32.9 (t, J = 4.3 Hz),
32.3 (dd, J = 135.1, 133.3 Hz), 26.3, 16.5 (d, J = 6.4 Hz), 16.5 (d,
J = 6.3 Hz), 16.4 (d, J = 5.3 Hz), 16.4 (d, J = 5.1 Hz).
31P NMR (283 MHz, CDCl3): δ = 23.12, 22.86.
HRMS: m/z [M + H]+ calcd for C20H32NO8P2: 476.1632; found:
476.1639.
Tetraethyl [2-(5-Oxo-2,4-diphenyl-4,5-dihydrooxazol-4-yl)eth-
ane-1,1-diyl]bis(phosphonate) (2e)
Following the general procedure (EtOAc–MeOH, 95:5) gave 2e as
a single regioisomer as a pale yellow oil; yield: 84.4 mg (63%).
1H NMR (700 MHz, CDCl3): δ = 8.10–8.07 (m, 2 H), 7.68–7.64 (m,
2 H), 7.61–7.57 (m, 1 H), 7.52–7.48 (m, 2 H), 7.37–7.33 (m, 2 H),
7.31–7.28 (m, 1 H), 4.15–4.05 (m, 8 H), 3.04–2.94 (m, 1 H), 2.92–
2.73 (m, 2 H), 1.29 (t, J = 7.1 Hz, 3 H), 1.27 (t, J = 7.1, Hz, 3 H),
1.26 (t, J = 7.1, Hz, 3 H), 1.25 (t, J = 6.9, Hz, 3 H).
13C NMR (176 MHz, CDCl3): δ = 177.8, 161.3, 139.7, 132.9, 128.8
(2 C), 128.7 (2 C), 128.3, 128.1 (2 C), 125.9, 125.5 (2 C), 71.7 (d,
J = 9.5 Hz), 62.8 (d, J = 6.2 Hz), 62.7 (d, J = 7.3 Hz), 62.7 (d, J =
6.5 Hz, 2 C), 35.6 (t, J = 4.1 Hz), 32.6 (t, J = 133.8 Hz), 16.3 (d, J =
6.2 Hz), 16.3 (d, J = 5.7 Hz, 2 C), 16.2 (d, J = 5.6 Hz).
31P NMR (101 MHz, CDCl3): δ = 23.58.
HRMS: m/z [M + H]+ calcd for C25H34NO8P2: 538.1755; found:
538.1758.
Tetraethyl (2-{4-[2-(Methylthio)ethyl]-5-oxo-2-phenyl-4,5-di-
hydrooxazol-4-yl}ethane-1,1-diyl)bis(phosphonate) (2f)
Following the general procedure (EtOAc–MeOH, 95:5) gave 2f as
a single regioisomer as a colorless oil; yield: 87.3 mg (65%).
1H NMR (700 MHz, CDCl3): δ = 8.02–7.98 (m, 2 H), 7.60–7.56 (m,
1 H), 7.50–7.46 (m, 2 H), 4.21–4.14 (m, 4 H), 4.13–4.03 (m, 4 H),
2.72 (dddd, J = 25.3, 23.7, 7.1, 3.0 Hz, 1 H), 2.64–2.47 (m, 2 H),
2.42 (ddd, J = 12.9, 9.7, 5.8 Hz, 1 H), 2.34 (ddd, J = 12.9, 10.3, 6.4
Hz, 1 H), 2.25–2.15 (m, 2 H), 2.04 (s, 3 H), 1.34 (t, J = 6.9 Hz, 3 H),
1.33 (t, J = 6.9 Hz, 3 H), 1.25 (t, J = 7.1 Hz, 3 H), 1.23 (t, J = 7.0
Hz, 3 H).
13C NMR (176 MHz, CDCl3): δ = 179.3, 161.5, 133.0, 128.9 (2 C),
128.2 (2 C), 125.9, 70.4 (dd, J = 8.7, 2.8 Hz), 63.1 (d, J = 6.3 Hz),
62.9 (d, J = 6.2 Hz, 2 C), 62.9 (d, J = 4.6 Hz), 38.5, 32.4 (t, J = 3.8
Hz), 32.0 (dd, J = 135.7, 133.3 Hz), 28.2, 16.5 (d, J = 6.5 Hz), 16.5
(d, J = 6.3 Hz), 16.4 (d, J = 5.2 Hz), 16.3 (d, J = 5.2 Hz), 15.5.
31P NMR (283 MHz, CDCl3): δ = 23.03, 22.81.
HRMS: m/z [M + H]+ calcd for C22H36NO8P2S: 536.1631; found:
536.1637.
Synthesis of Quaternary Amino Acids via Acid-Mediated Az-
lactone Ring Opening; General Procedure
An ordinary screw-cap vial was charged with a magnetic stirring
bar, the corresponding azlactone 2 (0.1 mmol, 1 equiv), and CH2-
Cl2–MeOH (1:1, 0.4 mL). Subsequently, TMSCl (0.2 mmol, 2
equiv) was added at 0 °C and the mixture was allowed to warm to
r.t. Reaction progress was monitored by TLC. After 24 h the solvent
was evaporated under reduced pressure and the residue was directly
subjected to flash chromatography (silica gel) to afford target prod-
uct 1.
Methyl 2-Benzamido-2-benzyl-4,4-bis(diethoxyphosphoryl)bu-
tanoate (1a)
Following the general procedure (EtOAc–hexane 9:1) gave 1a as a
pale yellow oil; yield: 33.6 mg (58%).
1H NMR (700 MHz, CDCl3): δ = 8.68 (s, 1 H), 7.98–7.93 (m, 2 H),
7.51–7.45 (m, 1 H), 7.44–7.41 (m, 2 H), 7.21–7.16 (m, 3 H), 7.09–
7.05 (m, 2 H), 4.19–4.03 (m, 6 H), 4.00–3.90 (m, 3 H), 3.81 (s, 3 H),
3.17 (d, J = 14.1 Hz, 1 H), 3.10–3.00 (m, 1 H), 2.41–2.31 (m, 1 H),
2.25 (dddd, J = 21.3, 18.3, 15.8, 2.3 Hz, 1 H), 1.34 (t, J = 7.2 Hz, 3
H), 1.32 (t, J = 7.0 Hz, 3 H), 1.25 (t, J = 7.1 Hz, 3 H), 1.17 (t, J =
7.1 Hz, 3 H).
13C NMR (176 MHz, CDCl3): δ = 172.5, 167.2, 136.4, 133.9, 131.6,
131.1 (2 C), 128.5 (2 C), 128.1 (2 C), 127.7 (2 C), 126.9, 63.8 (d,
J = 6.8 Hz), 63.4 (d, J = 6.5 Hz), 63.0 (d, J = 6.7 Hz), 62.9 (d, J =
6.8 Hz), 61.3 (dd, J = 6.8, 1.6 Hz), 52.7, 39.4, 30.5 (t, J = 134.6 Hz),
29.9 (t, J = 3.5 Hz), 16.6 (d, J = 5.7 Hz), 16.5 (d, J = 6.0 Hz), 16.4
(d, J = 5.7 Hz), 16.3 (d, J = 5.4 Hz).
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31P NMR (283 MHz, CDCl3): δ = 26.27 (d, J = 6.5 Hz), 22.96 (d,
J = 6.5 Hz).
HRMS: m/z [M + H]+ calcd for C27H40NO9P2: 584.2173; found:
584.2179.
Methyl 2-Benzamido-2-[2,2-bis(diethoxyphosphoryl)ethyl]-4-
methylpentanoate (1b)
Following the general procedure (EtOAc–hexane 9:1) gave 1b as a
yellow oil; yield: 29.1 mg (53%).
1H NMR (700 MHz, CDCl3): δ = 8.91 (s, 1 H), 8.01–7.99 (m, 2 H),
7.49–7.45 (m, 1 H), 7.44–7.40 (m, 2 H), 4.31–4.22 (m, 2 H), 4.18–
4.06 (m, 6 H), 3.75 (s, 3 H), 3.05 (tdd, J = 23.6, 6.3, 2.5 Hz, 1 H),
2.72 (dddd, J = 21.8, 15.8, 8.0, 6.3 Hz, 1 H), 2.46 (dd, J = 14.8, 6.9
Hz, 1 H), 2.23 (dddd, J = 21.5, 18.7, 15.7, 2.6 Hz, 1 H), 1.91 (dd,
J = 14.8, 5.2 Hz, 1 H), 1.71 (hd, J = 6.8, 5.2 Hz, 1 H), 1.38 (t, J =
7.1 Hz, 3 H), 1.33 (t, J = 7.1 Hz, 3 H), 1.32 (t, J = 7.1 Hz, 6 H), 0.98
(d, J = 6.7 Hz, 3 H), 0.86 (d, J = 6.6 Hz, 3 H).
13C NMR (176 MHz, CDCl3): δ = 173.1, 166.7, 134.0, 131.5, 128.5
(2 C), 127.6 (2 C), 63.7 (d, J = 7.0 Hz), 63.5 (d, J = 6.4 Hz), 63.0 (d,
J = 6.6 Hz), 62.9 (d, J = 6.8 Hz), 61.6 (d, J = 6.9, 2.2 Hz), 52.6, 42.2,
31.0 (t, J = 133.3 Hz), 30.9 (t, J = 3.6 Hz), 25.0, 24.4, 23.9, 16.6 (d,
J = 4.4 Hz), 16.5 (d, J = 4.4 Hz), 16.5 (d, J = 6.2 Hz), 16.4 (d, J =
5.9 Hz).
31P NMR (283 MHz, CDCl3): δ = 26.82 (d, J = 6.2 Hz), 23.10 (d,
J = 6.2 Hz).
HRMS: m/z [M + H]+ calcd for C24H42NO9P2: 550.2329; found:
550.2335.
Methyl 2-Benzamido-4,4-bis(diethoxyphosphoryl)-2-isopropyl-
butanoate (1c)
Following the general procedure (EtOAc–hexane 9:1) gave 1c as a
pale yellow oil; yield: 27.5 mg (51%).
1H NMR (700 MHz, CDCl3): δ = 8.63 (s, 1 H), 8.01–7.98 (m, 2 H),
7.49–7.46 (m, 1 H), 7.43–7.40 (m, 2 H), 4.31–4.22 (m, 2 H), 4.18–
4.04 (m, 6 H), 3.75 (s, 3 H), 3.08 (dddd, J = 25.8, 23.6, 5.9, 3.9 Hz,
1 H), 2.98 (hept, J = 7.0 Hz, 1 H), 2.54 (dddd, J = 20.2, 15.7, 12.0,
5.9 Hz, 1 H), 2.43 (dddd, J = 19.7, 17.1, 15.5, 4.0 Hz, 1 H), 1.39 (t,
J = 7.1 Hz, 3 H), 1.34–1.29 (m, 9 H), 1.13 (d, J = 6.8 Hz, 3 H), 0.96
(d, J = 6.9 Hz, 3 H).
13C NMR (176 MHz, CDCl3): δ = 172.3, 166.6, 134.0, 131.5, 128.5
(2 C), 127.5 (2 C), 63.8 (dd, J = 6.4, 4.6 Hz), 63.6 (d, J = 7.0 Hz),
63.3 (d, J = 6.6 Hz), 62.9 (d, J = 6.7 Hz), 62.8 (d, J = 6.9 Hz), 52.3,
31.2 (dd, J = 134.0, 131.7 Hz), 29.8, 26.8 (t, J = 3.8 Hz), 18.6, 18.3,
16.6 (d, J = 5.9 Hz, 2 C), 16.5 (d, J = 6.2 Hz), 16.4 (d, J = 5.7 Hz).
31P NMR (283 MHz, CDCl3): δ = 26.60 (d, J = 5.8 Hz), 23.28 (d,
J = 5.8 Hz).
HRMS: m/z [M + H]+ calcd for C23H40NO9P2: 536.2173; found:
536.2174.
Methyl 2-Benzamido-4,4-bis(diethoxyphosphoryl)-2-methylbu-
tanoate (1d)
Following the general procedure (EtOAc–hexane 9:1) gave 1d as a
colorless oil; yield: 23.8 mg (47%).
1H NMR (700 MHz, CDCl3): δ = 9.14 (s, 1 H), 8.07–8.01 (m, 2 H),
7.49–7.43 (m, 1 H), 7.43–740 (m, 2 H), 4.27 (ddq, J = 11.2, 7.0, 3.8
Hz, 2 H), 4.21–4.09 (m, 6 H), 3.75 (s, 3 H), 3.06 (dddd, J = 26.6,
24.0, 5.7, 2.8 Hz, 1 H), 2.47–2.31 (m, 2 H), 1.71 (s, 3 H), 1.39 (t, J =
7.0 Hz, 3 H), 1.34 (t, J = 7.3 Hz, 3 H), 1.34 (t, J = 7.1 Hz, 3 H), 1.33
(t, J = 7.3 Hz, 3 H).
13C NMR (176 MHz, CDCl3): δ = 172.7, 166.8, 133.6, 131.4, 128.3
(2 C), 127.5 (2 C), 63.5 (d, J = 6.5 Hz), 63.4 (d, J = 6.0 Hz), 62.9 (d,
J = 7.1 Hz), 62.9 (d, J = 7.0 Hz), 58.6 (dd, J = 6.6, 2.1 Hz), 52.5,
33.3 (t, J = 3.3 Hz), 30.8 (dd, J = 133.1, 133.0 Hz), 23.7, 16.4 (d, J =
4.8 Hz), 16.4 (d, J = 5.0 Hz), 16.3 (d, J = 6.2 Hz), 16.3 (d, J = 5.9
Hz).
31P NMR (283 MHz, CDCl3): δ = 26.35 (d, J = 6.6 Hz), 23.34 (d,
J = 6.6 Hz).
HRMS: m/z [M + H]+ calcd for C21H36NO9P2: 508.1860; found:
508.1866.
Methyl 2-Benzamido-4,4-bis(diethoxyphosphoryl)-2-phenylbu-
tanoate (1e)
Following the general procedure (EtOAc–hexane 9:1) gave 1e as a
pale yellow oil; yield: 24.4 mg (43%).
1H NMR (700 MHz, CDCl3): δ = 9.59 (s, 1 H), 8.16–8.09 (m, 2 H),
7.55–7.52 (m, 2 H), 7.52–7.50 (m, 1 H), 7.49–7.45 (m, 2 H), 7.35–
7.32 (m, 2 H), 7.28–7.26 (m, 1 H), 4.19–4.07 (m, 7 H), 4.06–3.99
(m, 1 H), 3.75 (s, 3 H), 2.96–2.79 (m, 2 H), 2.70 (tdd, J = 24.6, 6.2,
3.6 Hz, 1 H), 1.33–1.28 (m, 12 H).
13C NMR (176 MHz, CDCl3): δ = 171.8, 167.0, 138.3, 133.6, 131.8,
128.5 (2 C), 128.2 (2 C), 127.9 (2 C), 127.7, 127.4 (2 C), 64.8 (dd,
J = 7.4, 3.6 Hz), 63.3 (d, J = 5.1 Hz), 63.3 (d, J = 5.7 Hz), 63.2 (d,
J = 6.9 Hz), 63.1 (d, J = 6.5 Hz), 53.0, 34.3 (t, J = 3.0 Hz), 32.4 (dd,
J = 133.8, 131.7 Hz), 16.5 (d, J = 5.8 Hz), 16.5 (d, J = 4.2 Hz), 16.4
(d, J = 4.8 Hz), 16.4 (d, J = 3.9 Hz).
31P NMR (283 MHz, CDCl3): δ = 24.28 (d, J = 6.8 Hz), 24.04 (d,
J = 6.8 Hz).
HRMS: m/z [M + H]+ calcd for C26H38NO9P2: 570.2016; found:
570.2020.
Methyl 2-Benzamido-4,4-bis(diethoxyphosphoryl)-2-[2-(meth-
ylthio)ethyl]butanoate (1f)
Following the general procedure (EtOAc–hexane 9:1) gave 1f as a
yellow oil; yield: 31.9 mg (56%).
1H NMR (700 MHz, CDCl3): δ = 9.01 (s, 1 H), 8.05–7.99 (m, 2 H),
7.51–7.44 (m, 1 H), 7.42 (dd, J = 8.4, 7.0 Hz, 2 H), 4.31–4.23 (m, 2
H), 4.18–4.06 (m, 6 H), 3.77 (s, 3 H), 3.06 (dddd, J = 26.2, 23.5, 6.4,
2.2 Hz, 1 H), 2.86 (ddd, J = 14.3, 11.4, 5.1 Hz, 1 H), 2.65 (ddt, J =
22.1, 15.8, 6.7 Hz, 1 H), 2.52 (ddd, J = 12.9, 11.5, 5.2 Hz, 1 H), 2.44
(ddd, J = 12.8, 11.0, 5.1 Hz, 1 H), 2.31–2.23 (m, 1 H), 2.23–2.17 (m,
1 H), 2.06 (s, 3 H), 1.39 (t, J = 7.1 Hz, 3 H), 1.33 (t, J = 7.0 Hz, 3
H), 1.32 (t, J = 7.1 Hz, 6 H).
13C NMR (176 MHz, CDCl3): δ = 172.2, 166.8, 133.6, 131.7, 128.5
(2 C), 127.6 (2 C), 63.8 (d, J = 7.3 Hz), 63.6 (d, J = 6.5 Hz), 63.1 (d,
J = 6.5 Hz), 63.0 (d, J = 7.0 Hz), 61.2 (dd, J = 6.8, 1.5 Hz), 52.7,
35.0, 30.9 (t, J = 133.7 Hz), 30.8 (t, J = 2.8 Hz), 28.8, 16.6 (d, J =
3.3 Hz), 16.5 (d, J = 3.6 Hz), 16.5 (d, J = 6.1 Hz), 16.4 (d, J = 5.8
Hz), 15.7.
31P NMR (283 MHz, CDCl3): δ = 26.69 (d, J = 7.5 Hz), 22.83 (d,
J = 6.9 Hz).
HRMS: m/z [M + H]+ calcd for C23H40NO9P2S: 568.1894; found:
568.1899.
Tetraethyl ent-[2-(4-Isobutyl-5-oxo-2-phenyl-4,5-dihydrooxaz-
ol-4-yl)ethane-1,1-diyl]bis(phosphonate) (ent-2b) by Enantiose-
lective Michael Addition
An ordinary screw-cap vial was charged with a magnetic stirring
bar, CH2Cl2 (0.4 mL), tetraethyl vinylbisphosphonate (3a, 0.1
mmol, 1 equiv), and the corresponding catalyst 5 (0.02 mmol, 0.2
equiv). Subsequently, azlactone 4b (0.1 mmol, 1 equiv) was added
and the resulting mixture was stirred at r.t. for 24 h. After this time
the mixture was directly subjected to flash column chromatography
(silica gel) to afford target product ent-2b. Spectral data were in ac-
cordance with that of racemic 2b. The ee was determined by HPLC
(Chiralpak IC column, hexane–i-PrOH, 70:30, flow rate 1.0
mL/min): tR = 26.8 (major), 14.4 min (minor); [α]D20 –3.4 (c 1.14,
CHCl3).
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